Tag: antipsychotic withdrawal
Supportive patient-practitioner relationships are crucial to the successful discontinuation of psychiatric medication.
New guidance on how to taper and discontinue from psychiatric drugs from leading researchers Mark Horowitz and David Taylor.
A new article in Lancet Psychiatry debunks past studies claiming that those on low doses of antipsychotics are more likely to relapse.
An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.
A new study has found that of 10 people who were fully recovered from their first episode of schizophrenia (FES), those not taking antipsychotics did better in terms of cognitive, social, and role functioning—and reached full recovery more quickly.
Antipsychotics are big business, professionals are often at a loss as to how to help people going through disturbing experiences, the voices of patients are crowded out of the equation — there are many reasons for the lack of real education and informed consent around antipsychotics. To address this gap in knowledge, we launched a world study on antipsychotic medication withdrawal.
How can people come off psychiatric medications in the safest way? What are the key lessons and vital ingredients for leaving psychiatric care? Is there life after meds? Laura Delano spent 14 years as a psychiatric patient before she left behind her psychiatric diagnoses and reclaimed herself. Today she is Director of the Inner Compass Initiative and The Withdrawal Project, working to support drug withdrawal and build community beyond the mental health system.
A new study explores how people manage to discontinue antipsychotic medication and examines how social supports may improve outcomes.
With increasing evidence that psychiatric drugs do more harm than good over the long term, the field of psychiatry often seems focused on sifting through the mounds of research data it has collected, eager to at last sit up and cry, here’s a shiny speck of gold! Our drugs do work! One recently published study on withdrawal of antipsychotics tells of long-term benefits. A second tells of long-term harm. Which one is convincing?
I have given up on psychiatry as a system capable of “being there” for people who are dealing with life and death issues. Psychiatry as a system of care lacks validity. Every day — unfortunately — we learn of new examples proving this statement. But here's the good news: every day we meet people who show us that the predictions of psychiatry are not true; that there are “cures,” that it is possible to reduce or withdraw psychiatric drugs.
This week Live & Learn launched a research study on the experience of people labeled with mental disorders who have tried to stop taking psychiatric medications. This project -- the Psychiatric Medication Discontinuation/Reduction (PMDR) Study -- aims to understand the process of coming off psychiatric medications in order to better support those who choose to do so. The study seeks to answer the question: What helps people stop their psychiatric medications? What gets in the way of stopping?
The writings of Pies and his colleagues, I believe, provide a compelling case study of cognitive dissonance. Cognitive dissonance arises when people are presented with information that creates conflicted psychological states, challenging some belief they hold dear, and people typically resolve dissonant states by sifting through information in ways that protect their self-esteem and their financial interests. It is easy to see that process operating here.
For a long time I have felt that there just isn’t a good enough and long enough study on the pros and cons of long-term antipsychotic treatment versus reduction and discontinuation in people who have psychotic disorders, including those who are classified as having schizophrenia. Moreover, there are increasing reasons to be worried about the effects of long-term treatment with antipsychotics. I put this case to the UK’s National Institute of Health Research recently, and proposed that they fund a trial to assess the long-term outcomes of a gradual programme of antipsychotic reduction compared with standard ‘maintenance treatment.’ The NIHR agreed that this was an important issue, and that a new trial was urgently needed. The RADAR (Research into Antipsychotic Discontinuation And Reduction) study officially started in January 2016.
Last week was my anniversary off a huge psych drug cocktail I’d been on for 20 years. In this video I speak to the inner resources that kept me going. The fact is there is nothing in society to help those who love us to understand what we are going through.
So, thanks to everyone who has read and commented on my stories of reentry into the mental health system. I have now had eight nights of very good sleep and my mental health symptoms are back to the baseline. Baseline for me means I only get separated from consensus reality when a significant trauma occurs at the same time I'm having a pretty good sleep deficit. Usually I can manage it myself simply by being aggressive about handling — and increasing — the sleep. So this time I was unable to break that cycle and got some more drugs to help.